multipl
sclerosi
ms
inflammatori
demyelin
diseas
central
nervou
system
cn
varieti
clinic
present
profound
heterogen
ms
limit
symptom
neuroradiolog
histolog
appear
lesion
respons
therapi
expect
pathogenesi
ms
controversi
effect
treatment
halt
neuroaxon
damag
promot
remyelin
lead
caus
disabl
ms
affect
peopl
unit
state
million
peopl
worldwid
demyelin
plaqu
main
patholog
hallmark
ms
contain
promin
immunolog
respons
domin
cell
moreov
presenc
oligoclon
band
cerebrospin
fluid
ms
patient
show
presenc
immunoglobulinproduc
b
cell
suggest
particip
pathogenesi
diseas
find
suggest
ms
immunemedi
disord
involv
multipl
antigen
cn
ms
autoimmun
diseas
cn
understand
mechan
ms
essenti
elucid
possibl
strategi
repair
myelin
axon
structur
sever
criteria
establish
determin
whether
diseas
classifi
autoimmun
first
autoantigen
must
present
patient
proven
immun
respons
direct
second
one
must
identifi
autoantibodi
within
lesion
serum
patient
direct
correl
diseas
activ
observ
clinic
improv
immunosuppress
treatment
system
lupu
erythemat
sle
wellcharacter
autoimmun
disord
present
autoantigen
cell
promot
antibodi
format
henc
clinic
manifest
also
critic
reproduc
clinic
histopatholog
aspect
human
diseas
administr
autoantibodi
autoantigen
within
anim
exampl
transfer
antidna
antibodi
recipi
mice
immunolog
reaction
glomerular
antigen
lead
nephropathi
similar
seen
sle
diseas
like
sle
experimentalbas
extens
literatur
meet
criteria
prove
role
autoimmun
pathophysiolog
ms
also
organspecif
diseas
brain
spinal
cord
immunemedi
myelin
destruct
nevertheless
extens
research
confirm
specif
autoantigen
ms
lack
absencepres
infecti
agent
patient
ms
also
proven
organspecif
immunemedi
diseas
herp
enceph
persist
exogen
antigen
case
herp
viru
resid
cn
drive
develop
acut
inflamm
necrot
lesion
howev
absenc
consist
viral
bacteri
antigen
ms
patient
suggest
presenc
autoantigen
drive
diseas
antibodi
direct
cn
myelin
protein
lipid
carbohydr
possibl
candid
autoantigen
identifi
tissu
serum
patient
ms
extens
literatur
devot
identifi
antibodi
myelin
oligodendrocyt
glycoprotein
mog
ms
patient
inconsist
result
enzymelink
immunosorb
assaybas
bind
studi
use
synthet
mog
peptid
identifi
antibodi
found
increas
frequenc
mogbind
igg
patient
ms
compar
control
contrast
studi
use
enzymelink
immunosorb
assay
bind
recombin
human
immunoglobulin
domain
mog
show
differ
level
bound
antibodi
patient
ms
healthi
control
use
techniqu
immunoblot
detect
antibodi
direct
recombin
human
immunoglobulin
domain
mog
patient
ms
result
inconsist
antibodi
bind
antigen
alphabcrystallin
alu
repeat
myelin
basic
protein
myelinassoci
glycoprotein
report
rigor
studi
despit
sever
publish
attempt
detect
quantifi
antibodi
direct
lemu
et
al
myelin
nonmyelin
antigen
patient
ms
consensu
lack
selfdirect
immun
respons
produc
antibodi
argu
hypothesi
ms
autoimmun
diseas
fig
hand
neuromyel
optica
nmo
autoimmun
astrocytopathi
cn
diseas
driven
presenc
antibodi
aquaporin
plasma
membranebas
watertransport
protein
see
fig
abund
water
channel
brain
express
primarili
astrocyt
highli
involv
neuroexcit
discoveri
pathogen
immunoglobulin
g
direct
almost
patient
nmo
first
evid
diseas
inflammatori
autoimmun
diseas
cn
pathogen
igg
nmo
patient
reproduc
vivo
presenc
confirm
patholog
lesion
compar
ms
autoimmun
diseas
like
neuromyel
optica
clear
ms
meet
full
definit
autoimmun
diseas
tabl
although
nmo
meet
autoimmun
diseas
criteria
ms
meet
although
data
sever
criteria
evid
controversi
exampl
multipl
studi
focus
measur
level
precursor
cell
clinic
exacerb
howev
none
studi
found
differ
preval
healthi
control
confirm
use
patient
popul
clear
data
weak
make
definit
conclus
ms
autoimmun
diseas
viral
microorgan
postul
mani
investig
causal
agent
ms
idea
plausibl
demyelin
diseas
cn
like
progress
multifoc
leukoencephalopathi
caus
viru
jc
viru
immunecompromis
individu
recent
much
attent
focus
epsteinbarr
viru
ebv
ebv
antigen
express
significantli
higher
level
cerebrospin
fluid
serum
ms
patient
compar
control
howev
studi
show
absenc
intrathec
antiebv
antibodi
synthesi
nearli
patient
ms
argu
hypothesi
henc
associ
ebv
adult
ms
well
establish
role
pathogenesi
remain
determin
viral
agent
like
varicella
zoster
rubella
consid
possibl
risk
factor
causal
agent
note
vitamin
defici
link
causal
agent
relaps
remit
ms
vitamin
role
regul
immun
function
low
level
vitamin
could
produc
immunedefici
state
viral
agent
although
clinic
trial
observ
studi
use
high
level
vitamin
shown
modest
reduct
level
interleukin
seen
inflammatori
marker
fact
high
dose
treatment
vitamin
ms
patient
scant
effect
overal
cours
diseas
support
theori
demyelin
diseas
nearli
ident
human
ms
consist
establish
anim
use
wellcharacter
viral
agent
theiler
murin
encephalomyel
viru
tmev
mous
enter
pathogen
belong
picornaviru
famili
produc
chronic
progress
demyelin
condit
similar
seen
human
progress
ms
model
present
immun
respons
viral
infect
cell
autoimmun
respons
cn
antigen
novel
therapi
like
natur
human
antibodi
induc
either
remyelin
neuroprotect
success
evalu
model
virusinduc
demyelin
virusinduc
model
persist
viral
infect
without
dramat
anim
mortal
coronaviru
jhm
semliki
forest
affect
mice
distemp
viru
specif
canin
visna
viru
sheep
goat
demyelin
major
patholog
hallmark
ms
suffici
explain
deficit
seen
patient
first
observ
demyelin
complet
axon
dysfunct
cn
made
sinc
mani
consid
uniqu
event
recent
studi
found
ms
damag
myelin
enough
produc
spectrum
symptom
human
level
demyelin
strictli
correl
diseas
stage
neurolog
deficit
lesion
patholog
imag
studi
postmortem
brain
use
mri
shown
axon
injuri
primari
event
lead
clinic
deficit
demyelin
hand
murin
model
demyelin
also
question
role
demyelin
sole
event
ms
despit
profound
demyelin
seen
tmev
murin
model
absenc
major
histocompat
complex
mhc
class
deficit
motor
function
moreov
preserv
axon
transport
mice
despit
demyelin
cell
direct
recognit
mch
class
wellknown
mediat
axon
injuri
dropout
murin
model
demyelin
murin
cultur
neuron
cell
injur
demyelin
axon
select
clone
domin
cell
activ
ms
lesion
direct
correl
accumul
amyloid
precursor
protein
marker
acut
axon
damag
perforin
critic
mediat
cell
cytotox
apoptosi
releas
cell
recognit
mch
class
complex
insid
cell
perforin
creat
pore
membran
deliv
granzym
initi
cascad
signal
caus
death
cell
viral
infect
tmev
electr
silent
neuron
vitro
increas
express
mch
class
complex
importantli
axon
injuri
secondari
demyelin
mediat
inflammatori
factor
especi
perforin
perforindefici
mice
increas
number
largediamet
axon
better
function
motor
abil
compar
perforincompet
control
despit
level
demyelin
sodium
channel
also
critic
compon
demyelin
axon
chang
number
influenc
impuls
conduct
acut
injuri
peripher
axon
high
densiti
sodium
channel
murin
model
multipl
sclerosi
demyelin
also
shown
format
node
ranvier
action
potenti
gener
saltatori
conduct
preced
remyelin
axon
demyelin
demyelin
mice
mhc
class
defici
normal
function
statu
previous
describ
normal
motor
function
caus
preserv
axon
increas
intens
sodium
channel
suggest
upregul
redistribut
molecul
axon
base
observ
conclud
axon
injuri
play
critic
role
neurolog
deficit
seen
patient
ms
must
taken
account
consid
strategi
ms
therapi
understand
complex
etiolog
ms
import
axon
integr
critic
clinician
expect
halt
neuroaxon
damag
patient
newli
diagnos
ms
first
neurolog
symptom
alreadi
axon
loss
henc
need
treat
earli
use
multipl
strategi
target
remyelin
preserv
axon
oligodendrocyt
ol
author
laboratori
done
extens
research
natur
human
recombin
antibodi
formerli
known
molecul
part
human
innat
immunoglobulin
repertoir
abl
bind
oligodendrocyt
neuron
tmev
lysolecithininduc
demyelin
promot
oligodendrocyt
remyelin
protect
spinal
cord
axon
number
current
molecul
clinic
trial
establish
toler
ms
patient
acut
exacerb
addit
protect
axon
injuri
tmev
amyotroph
later
sclerosi
murin
model
also
bind
psancam
gangliosid
glia
neuron
result
neurit
extens
vitro
neurit
outgrowth
recent
show
immunemodulatori
therapeut
effect
moginduc
experiment
autoimmun
encephalomyel
eae
inhibit
leucin
rich
repeat
immunoglobulinlik
domain
contain
nogo
receptor
interact
increas
differenti
oligodendrocyt
progenitor
cell
matur
oligodendrocyt
tmev
murin
model
demyelin
inhibit
molecul
promot
remyelin
lead
discoveri
first
drug
enter
clinic
trial
show
patient
improv
nerv
signal
possibl
myelin
repair
despit
fail
improv
disabl
cognit
function
week
followup
explain
previou
section
cell
upregul
mhc
class
complex
critic
pathogenesi
ms
dimethyl
fumar
tecfidera
molecul
show
remark
efficaci
treatment
relaps
remit
ms
exposur
may
result
reduct
tcell
popul
certain
patient
fingolimod
first
approv
oral
therapi
activ
relaps
remit
ms
modul
tcell
prolifer
vitro
well
togeth
result
suggest
immunotherapi
activ
cell
use
antibodi
could
suppress
immunemedi
reaction
patient
ms
ms
immunemedi
diseas
lack
presenc
specif
antigen
drive
inflammatori
process
extens
character
ms
patholog
immunolog
serolog
misl
mani
investig
conclud
ms
autoimmun
diseas
howev
lack
scientif
evid
support
role
activ
autoantigen
autoantibodi
drive
inflammatori
demyelin
cascad
seen
patient
ms
understand
role
axon
injuri
relationship
clinic
deficit
essenti
futur
drug
futur
trial
aim
multifacet
approach
sever
reagent
target
remyelin
protect
axon
oligodendrocyt
progenitor
cell
suppress
therapi
activ
inflammatori
cell
popul
